Premium
[P3–253]: REAL WORLD ADMINISTRATION OF THE ALZHEIMER's DISEASE ASSESSMENT SCALE‐COGNITIVE
Author(s) -
Black Christopher M.,
Ritchie Craig W.,
Wood Robert,
Khandker Rezaul Karim,
Jones Eddie,
Ambegaonkar Baishali M.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1467
Subject(s) - dementia , medicine , demographics , clinical trial , disease , cognition , clinical practice , cog , scale (ratio) , family medicine , psychiatry , demography , geography , cartography , artificial intelligence , sociology , computer science
Background: The Alzheimer’s disease assessment scale-cognitive (ADAS-Cog) is the preferred efficacy measure in Alzheimer’s disease (AD) clinical trials but is rarely used in real-world practice ADAS-cog data generated in the real-world could be used to facilitate a better understanding of the clinical and economic meaningfulness of ADAS-cog changes observed during trials. The objective of this analysis was to estimate the frequency of ADAS-cog use in the real-world and describe the characteristics of administering physicians and their patients. Methods: Data were taken from the 2015/16 Adelphi RealWorld Dementia Disease Specific Programme, a cross-sectional survey of physicians, and their patients with cognitive impairment (CI) in the UK, France, Italy, Germany, Spain, Canada and the US. Physicians completed interviews about their clinical knowledge and practice setting and also completed record forms, containing patient demographics, clinical characteristics, diagnosis and tests/scales performed to aid diagnosis. Results: While 71% (n1⁄4534) of all physicians surveyed (n1⁄4757) were aware of the ADAS-Cog, only 40% (n1⁄4211) used the ADAS-Cog in clinical practice with varying levels of frequency: 9.5% very often, 22.4% often, 52.4% occasionally and 15.7% rarely. Physicians who administered the ADAS-Cog were more likely to be neurologists (48.8% vs. 37.6%, p1⁄40.0410), deliver care at memory clinics (50.5% vs. 25.5%, p<0.0001), or were currently involved in CI/dementia clinical trials (10.6% vs.